Avenue therapeutics, inc. (ATXI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating expenses:
Research and development

697

3,855

1,706

6,392

10,241

2,715

1,788

3,754

9,439

4,118

2,000

447

133

163

183

421

564

General and administrative

577

619

617

716

1,119

1,387

820

927

986

1,104

848

1,297

371

304

200

217

276

Loss from operations

-1,274

-5,474

-2,323

-7,108

-11,360

-4,102

-2,608

-4,681

-10,425

-6,325

-2,848

-1,744

-504

-516

-383

-638

-840

Interest income

32

59

81

126

91

8

13

24

48

82

6

0

0

-

0

-

-

Interest expense

-

-

-

-

-

-

-

-

-

0

106

93

95

159

89

87

85

Interest expense - related party

-

-

-

-

-

-

-

-

-

0

0

20

61

60

53

46

33

Change in fair value of convertible notes payable

-

-

-

-

-

-

-

-

-

0

0

95

4

-89

0

0

89

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

0

0

454

-3

169

19

0

0

Net Loss

-1,242

-5,415

-2,242

-6,982

-11,269

-3,919

-2,595

-4,657

-10,377

-6,243

-2,948

-2,406

-661

-815

-544

-771

-1,047

Net loss per common share outstanding, basic and diluted

-0.08

-0.26

-0.14

-0.43

-0.82

-0.37

-0.25

-0.45

-1.03

-0.63

-0.30

-0.70

-0.22

-1.45

0.19

0.28

-0.13

Weighted average number of common shares outstanding, basic and diluted

16,474

16,452

16,376

16,314

13,742

10,309

10,295

10,251

10,099

10,084

9,972

3,459

3,022

-2,503

2,848

2,785

8,310